Health

FDA clears OrthoPediatrics' pediatric thigh-bone nail system; first surgeries done

Warsaw, Indiana • October 27, 2026 • By Press Pass USA

Editorial illustration: a pediatric orthopedic operating room with a surgeon holding a small implant tray

Editorial illustration — Press Pass USA

OrthoPediatrics on Tuesday announced U.S. Food and Drug Administration clearance of its Pediatric Nailing Platform Femur Retrograde Nail System, a set of implants designed specifically for children's thigh bones, and said the first procedures using the system have already been completed.

The system, developed with a team of pediatric orthopedic surgeons, is intended for pediatric femoral trauma and deformity correction. It includes anatomic nails for trauma cases and straight nails for deformity, and builds on the company's earlier Femur and Tibia launches using the same instrumentation. The new instruments are meant to simplify complex varus/valgus and coronal/sagittal plane correction procedures — the angular and rotational realignments surgeons perform on growing bones.

The clearance addresses what the company calls an important unmet need: implants sized and shaped for pediatric anatomy rather than scaled-down adult hardware. “With the first surgical case already complete, we are encouraged by the initial adoption of this latest addition to our platform,” said Joe Hauser, the company's chief executive. OrthoPediatrics says its Pediatric Nailing Platform has supported nearly 15,000 patients worldwide.

A 510(k) clearance means the FDA found the device substantially equivalent to a legally marketed device; it is not the same as a new-drug approval, and the company did not report clinical outcome data for the new system in its announcement.

Sources: OrthoPediatrics Corp. via GlobeNewswire (Oct 27, 2026); Morningstar (Oct 27, 2026).